CIBC Private Wealth Group
CALT

CIBC Private Wealth Group’s Calliditas Therapeutics AB American Depositary Shares CALT Stock Holding History

CIBC Private Wealth Group’s Portfolio CALT Stock Details CALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-14
Closed -$546 – 3327
2024
Q2 		$546 Buy
+14
New +$385 ﹤0.01% 2968

Other funds holding CALT

CGH
Crossmark Global Holdings Houston, Texas $7.71B AUM 37.66% 1-Year Est. Return
AP
Advisors Preferred Rockville, Maryland $679M AUM 22.19% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $117B AUM 29.66% 1-Year Est. Return
MTIC
Missouri Trust & Investment Company Springfield, Missouri $341M AUM 17.31% 1-Year Est. Return

CIBC Private Wealth Group's CALT Position: Q3 2024 in Review

CIBC Private Wealth Group sold out of Calliditas Therapeutics AB American Depositary Shares (CALT) in Q3 2024, closing a stake of 14 shares — an estimated $546 sold.

CIBC Private Wealth Group first reported a position in CALT in Q2 2024 and held it in 1 quarter. The position peaked at $546 in Q2 2024. 5 funds tracked by Wall St. Rank hold CALT as of Q3 2024.

  • CIBC Private Wealth Group reported no remaining Calliditas Therapeutics AB American Depositary Shares position as of Q3 2024 after selling out during the quarter.
  • CIBC Private Wealth Group sold 14 Calliditas Therapeutics AB American Depositary Shares shares in Q3 2024, an estimated $546.
  • CIBC Private Wealth Group first reported a position in Calliditas Therapeutics AB American Depositary Shares in Q2 2024 and held it in 1 quarter.
  • CIBC Private Wealth Group's Calliditas Therapeutics AB American Depositary Shares position peaked at $546 in Q2 2024.
  • 5 funds tracked by Wall St. Rank held Calliditas Therapeutics AB American Depositary Shares as of Q3 2024.

Based on CIBC Private Wealth Group's 13F filing for Q3 2024, filed 13 Nov 2024.